Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Química Sintética S A has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. While these actions are both located within 1 distinct art unit, they are being handled by 2 distinct examiners, providing different perspectives within the same technical department. This arrangement allows the company to observe how different individuals interpret the same art unit's guidelines during the examination process.
JACKSON, SHAWQUIA is the busiest examiner, currently overseeing 1 busiest examiner pending action. Since the 2 pending office actions are split between separate individuals, the company must address the specific nuances of each examiner despite the shared 1 distinct art unit classification. This split workload suggests that while the technology is concentrated, the human element of the prosecution is diversified across the distinct examiners involved in the portfolio. The company's success in the Biotechnology & Pharmaceuticals area depends on navigating these individual examiner preferences.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.3% |
| NOTTINGHAM, KYLE GREGORY | 1 | 61.7% | +31.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574513 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | NOTTINGHAM, KYLE GREGORY | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574513 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | NOTTINGHAM, KYLE GREGORY | 21d |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18842157 | CRYSTALLINE FORM OF DAROLUTAMIDE | JACKSON, SHAWQUIA | — | §112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18574513 | PROCESSES FOR THE PREPARATION OF NON-STEROIDAL ANTIANDROGENS | NOTTINGHAM, KYLE GREGORY | 1621 | §103§112 | Final Rejection | 21d | Pending | Dec 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial